Patents Assigned to SuperGen, Inc.
-
Patent number: 6509370Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structures R1COOR2, R1CONR2, and R1COR2, wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.Type: GrantFiled: July 9, 2002Date of Patent: January 21, 2003Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Ashok Y. Gore, Joseph Rubinfeld, Rajesh Shrotriya
-
Patent number: 6497896Abstract: A method for administering a camptothecin to a patient comprising: injecting into a patient a pharmaceutical composition comprising an aqueous suspension of microdroplets suitable for intravenous delivery, the microdroplets having a mean diameter between 200 Angstroms and one micron, the microdroplets comprising a substantially water-insoluble, pharmacologically acceptable liquid, a camptothecin dissolved in the water-insoluble, pharmacologically acceptable liquid, and an outer layer comprising a phospholipid. The pharmaceutical composition is particularly well suited for delivering camptothecins, particularly 9-nitro-camptothecin intravenously.Type: GrantFiled: February 12, 2001Date of Patent: December 24, 2002Assignees: SuperGen, Inc., R T P Pharma Inc.Inventors: Howard Sands, Awadhesh Mishra
-
Patent number: 6489369Abstract: A pharmaceutical formulation comprising a pharmaceutically active agent, which is insoluble or sparingly soluble in water and a sterol phosphocholine surfactant.Type: GrantFiled: January 28, 2000Date of Patent: December 3, 2002Assignee: SuperGen, Inc.Inventors: Bruce H. Morimoto, Peter L. Barker, Vincent Hernandez, Cass K. Piper
-
Patent number: 6485514Abstract: Disclosed are implants, stents, catheters, methods and kits for the local delivery of therapeutic agents that are preferentially cytotoxic or cytostatic with regards to proliferating cells to sites where proliferative cells are present.Type: GrantFiled: December 12, 1997Date of Patent: November 26, 2002Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Patent number: 6482830Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 149.2 and 151.2° C., an exotherm at between 162.6 and 164.6° C., and an exotherm at between 272 and 274° C.Type: GrantFiled: February 21, 2002Date of Patent: November 19, 2002Assignee: SuperGen, Inc.Inventors: Sanjeev Redkar, Ashok Gore
-
Publication number: 20020165127Abstract: The present invention is directed to compositions and methods for treating insulin resistance and for ameliorating pathological conditions associated with insulin resistance. Also disclosed are methods for identifying patients at risk for developing non-insulin dependent diabetes melitis or insulin resistance. Also disclosed are methods for identifying patients at risk for developing or suffering from reactive hypoglycemia and methods of treatment thereof.Type: ApplicationFiled: February 19, 2002Publication date: November 7, 2002Applicant: SuperGen, Inc.Inventor: Fred I. Chasalow
-
Patent number: 6420378Abstract: A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.Type: GrantFiled: April 20, 2000Date of Patent: July 16, 2002Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6319943Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharrnaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structures R1COOR2, R1CONR2, and R1COR2, wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.Type: GrantFiled: September 20, 2000Date of Patent: November 20, 2001Assignee: SuperGen, IncInventors: Rajashree Joshi, Ashok Y. Gore, Joseph Rubinfeld, Rajesh Shrotriya
-
Patent number: 6316435Abstract: Disclosed are methods and kits for treating lymphoproliferative diseases in a host including (co)administering to the host pentostatin, at least one alkylating agent and at least one methylated xanthine.Type: GrantFiled: February 24, 1999Date of Patent: November 13, 2001Assignee: SuperGen, Inc.Inventors: John C. Byrd, Michael R. Grever, Ian W. Flinn, Jamie K. Waselenko
-
Patent number: 6284747Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: October 5, 2000Date of Patent: September 4, 2001Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6281223Abstract: Disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including coadministering the radiation and an orally dosed camptothecin derivative to the host being treated for cancer. Also disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including orally dosing the host being treated for cancer with a camptothecin derivative; and administering radiation at a point when a serum concentration of the camptothecin derivative in the host being treated for cancer reaches about 50% or more of the maximum concentration achieved by the oral dose.Type: GrantFiled: April 13, 1999Date of Patent: August 28, 2001Assignee: SuperGen, Inc.Inventors: Hak Choy, Luigi Lenaz
-
Patent number: 6218374Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: July 2, 1999Date of Patent: April 17, 2001Assignee: Supergen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6191119Abstract: A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antibiotic agent such as doxorubicin.Type: GrantFiled: October 15, 1999Date of Patent: February 20, 2001Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6174873Abstract: Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.Type: GrantFiled: November 4, 1998Date of Patent: January 16, 2001Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Patent number: 6136846Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structuresR.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, and R.sub.1 COR.sub.2,wherein R.sub.1 is a hydrophobic C.sub.3 -C.sub.50 alkane, alkene or alkyne and R.sub.2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.Type: GrantFiled: October 25, 1999Date of Patent: October 24, 2000Assignee: Supergen, Inc.Inventors: Joseph Rubinfeld, Ashok Y. Gore, Rajashree Joshi, Rajesh Shrotriya
-
Patent number: 6048845Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: August 28, 1998Date of Patent: April 11, 2000Assignee: Supergen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6017948Abstract: Disclosed are compositions comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent, together with kits comprising the composition and methods of using the composition.Type: GrantFiled: October 30, 1998Date of Patent: January 25, 2000Assignee: Supergen, Inc.Inventors: Joseph Rubinfeld, Ashok Y. Gore, Rajashree Joshi, Rajesh Shrotriya
-
Patent number: 5985302Abstract: Methods, compositions and a kit for deactivating spills or leaks of HIV infected blood or anticancer drugs by applying to the leak or spill an aqueous solution containing calcium hypochlorite or sodium hypochlorite as the active ingredient. In order to thicken the aqueous solution and thus keep it from spreading beyond its intended area of application, the solution of calcium hypochlorite contains methylcellulose. In addition to chemically deactivating the active anticancer drug, the solution of the invention also effectively decolorizes it, thus preventing permanent stains on any surface or fabric with which the anticancer drug comes into contact.Type: GrantFiled: July 10, 1998Date of Patent: November 16, 1999Assignee: Supergen, Inc.Inventors: Robert T. Dorr, David S. Alberts
-
Patent number: 5824668Abstract: Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.Type: GrantFiled: November 7, 1996Date of Patent: October 20, 1998Assignee: Supergen, Inc.Inventors: Joseph Rubinfeld, Julius A. Vida, H. Leon Bradlow, Elliott L. Fineman
-
Patent number: 5804568Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: February 3, 1997Date of Patent: September 8, 1998Assignee: Supergen, Inc.Inventor: Joseph Rubinfeld